MediWound Q1 Earnings Call Highlights
MediWound (NASDAQ:MDWD) reported a wider first-quarter loss and lower revenue compared with the prior-year period, while management reaffirmed its 2026 revenue outlook and said it continued to advance...
MediWound Ltd. Advances Development with EscharEx IND Submission Planned for Year-End and NexoBrid FDA Pediatric Approval
MediWound announces NexoBrid pediatric approval, EscharEx trial launch, financing secured, and exceeding product demand as manufacturing expands.Quiver AI SummaryMediWound Ltd. recently announced significant...